1-1 of 1
Adrien Briaux
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results

Jacques Vargaftig, MD PhD, Hassan Farhat, MD, Lionel Ades, MD PhD, Adrien Briaux, Camille Benoist, Isabelle Turbiez, Norbert Vey, MD PhD, Sylvie Glaisner, MD, Céline Callens, PharmD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5233.
https://doi.org/10.1182/blood-2018-99-117485
Published: 2018